The genetic and pharmacologic inhibition of NLRP3 suppressed PMN-MDSCs tumor infiltration and significantly augmented the efficacy of anti-PD-1 antibody immunotherapy in melanoma (90). This evidence concerns the gene PDCD1 and melanoma.